There is an old belief and practice that an aspirin a day truly keeps cardiovascular disease at bay in lower-risk individuals but now by a study, ARRIVE trial at the European Society of Cardiology (ESC) Congress 2018, published the Lancet, it remains unanswered, despite the efforts of a 12,000-patient randomized controlled trial that set out to settle the issue. “While no overall reduction was observed in the primary composite endpoint of CV events, results from ARRIVE are generally consistent with many other studies that tended to demonstrate aspirin’s ability to lower the risk of first nonfatal MI without affecting the risk of total stroke,” said researcher The role of aspirin in the secondary prevention of coronary disease and stroke, as well as in the setting of acute MI and stroke, is well established.
But as he reminded his audience, the use of aspirin for primary prevention has…
